Assessing Ascendis Pharma's 2025 Valuation After Big Run and DCF Upside Potential [Yahoo! Finance]
Ascendis Pharma A/S - American Depositary Shares (ASND)
Last ascendis pharma a/s - american depositary shares earnings: 11/18 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ascendispharma.com
Company Research
Source: Yahoo! Finance
Despite a choppy recent stretch, with the stock down 9.3% over the last week and 5.0% over the last month, Ascendis is still up 44.9% year to date and 46.6% over the past year, which indicates that investors are increasingly optimistic about its long-term pipeline. Much of that momentum has been driven by growing confidence in TransCon-based therapies and regulatory progress that has reinforced the commercial potential of its growth hormone franchise. At the same time, renewed interest in late-stage candidates and periodic analyst upgrades have kept Ascendis on the radar of growth-focused biotech investors. On our valuation framework, Ascendis scores a 5 out of 6 , suggesting it screens as undervalued on most checks. Next, we will break down what different valuation methods indicate about that price tag, before finishing with a more nuanced way of thinking about what the stock might really be worth. Ascendis Pharma delivered 46.6% returns over the last year. See how this stacks
Show less
Read more
Impact Snapshot
Event Time:
ASND
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ASND alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ASND alerts
High impacting Ascendis Pharma A/S - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
ASND
News
- Here's My Prediction For Who Could Acquire Ascendis Pharma [Seeking Alpha]Seeking Alpha
- Assessing Ascendis Pharma (ASND)'s Valuation After a Strong 69.72% One-Year Shareholder Return [Yahoo! Finance]Yahoo! Finance
- Ascendis Pharma gains amid takeover speculation [Seeking Alpha]Seeking Alpha
- Ascendis Pharma A/S (NASDAQ:ASND) had its price target raised by analysts at Stifel Nicolaus from $254.00 to $256.00. They now have a "buy" rating on the stock.MarketBeat
- Former Novo Nordisk Executive Jesper Høiland Joins Alva Therapeutics' Board of DirectorsPR Newswire
ASND
Earnings
- 11/12/25 - Miss
ASND
Sec Filings
- 12/10/25 - Form 6-K
- 12/4/25 - Form 144
- 12/2/25 - Form 144
- ASND's page on the SEC website